[PCN153] Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy
HomePublications[PCN153] Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy
[PCN153] Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy
2015 Value in Health
Aiello, A. | Daniel, F. | D’Ausilio, A. | Snedecor, S. J. | Toumi, M. |
Volume: 18,
Issue: 7,
Pages: A457,
To assess the cost-utility of first-line nilotinib vs imatinib in patients with chronic myeloid leukaemia (CML) eligible to start the treatment-free remission (TFR) phase in the Italian healthcare setting (NHS).
